Zero Tolerance – Mitigating the Opioid Epidemic Amongst Minimally Invasive Urologic Patients

Daniella Wong  
*Thomas Jefferson University, daniella.wong@jefferson.edu*

Thenappan Chandrasekar, MD  
*Thomas Jefferson University, thenappan.chandrasekar@jefferson.edu*

Costas Lallas, MD  
*Thomas Jefferson University, costas.lallas@jefferson.edu*

Follow this and additional works at: [https://jdc.jefferson.edu/si_ctr_2022_phase1](https://jdc.jefferson.edu/si_ctr_2022_phase1)

Part of the Anesthesiology Commons, Surgery Commons, and the Translational Medical Research Commons

Let us know how access to this document benefits you

**Recommended Citation**  
Wong, Daniella; Chandrasekar, MD, Thenappan; and Lallas, MD, Costas, "Zero Tolerance – Mitigating the Opioid Epidemic Amongst Minimally Invasive Urologic Patients" (2020). *Phase 1*. Paper 6.  
[https://jdc.jefferson.edu/si_ctr_2022_phase1/6](https://jdc.jefferson.edu/si_ctr_2022_phase1/6)

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning (CTL)](https://jefferson.edu/ctl). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Phase 1 by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Zero Tolerance – Mitigating the Opioid Epidemic Amongst Minimally Invasive Urologic Patients

Daniella Wong, Thenappan Chandrasekar, MD*, Costas Lallas, MD*

(*) indicates primary project advisor

Introduction: Opioids are routinely prescribed following minimally invasive surgery (MIS), yet the majority of medication remains unused. However, the literature is lacking evidence for non-narcotic analgesia in MIS urologic procedures. The purpose of this study is to evaluate the efficacy of a non-narcotic postoperative pain management regimen in reducing opioid use following MIS urologic procedures.

Methods: In this prospective study, 51 MIS urologic patients were recruited over two months. Patients in the first month cohort (P1) were managed with the established pain management standard-of-care, while patients in the second month (P2) followed a non-narcotic postoperative pain management protocol that included an “opt-in” requirement for opioids. Protocol efficacy was assessed using self-reported patient pain scores at three time points, total postoperative hospital opioid utilization, and the need for opioids at discharge. Data analysis included descriptive statistics and student’s t-test.

Results: Total mean values revealed 27.9% reduction in morphine equivalent dose (MED) prescribed, 19.7% reduction in MED used by patients, and 70% reduction in
number of patients prescribed any opioids at time of discharge in P2 patients compared to P1 patients (p-value <0.001). There was no significant difference between P1 and P2 in patient pain scores at each time point.

**Discussion:** Overall, the new non-narcotic pain management protocol reduced postoperative opioid utilization in patients undergoing urologic MIS without compromising pain control. This study demonstrates that instituting a single “opt-in” postoperative pain management protocol with appropriate patient education helped significantly reduce the use of postoperative opioids.